Today: 14 June 2026
Browse Category

NASDAQ:BENF 22 October 2025 - 9 December 2025

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Aimei Health Technology shares surged 968% to $85.47 Tuesday after the SPAC extended its merger deadline to January 6, 2026, fueling speculation of a pending deal. The S&P 500 closed down 0.02%, while microcap stocks dominated gains, with Oriental Culture Holding up 321% and Netcapital up 122%. Trading in AFJK exceeded 6 million shares, far above its average.
9 December 2025
··········
Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Beneficient stock surged 64% to $0.80 after hours Oct. 21 following Chairman Thomas O. Hicks and Interim CEO James Silk converting $52.6 million of preferred units into Class A shares. The move aims to meet Nasdaq’s minimum equity rules after the company posted a Q1 FY2026 GAAP net loss of $7.19 per share. Zacks maintains a $2.00 price target, but ChartMill rates the company’s fundamentals 1/10.
22 October 2025
·

Stock Market Today

  • Indivior's Chief Scientific Officer Sells Shares Amid Stock Rally: Investor Implications
    June 14, 2026, 12:02 AM EDT. Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals, sold 18,586 shares valued at $707,383 on June 11, 2026, representing 7.54% of his holdings. Post-sale, he retains 227,923 shares worth about $8.69 million, maintaining a 0.18% stake. The sale occurred during a significant stock price surge, with Indivior shares rising 177% over the past year, reflecting strong market performance amid growth in opioid dependence therapies. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, not signaling insider concerns. Indivior's strategy focuses on buprenorphine-based addiction treatments, with $1.29 billion in trailing twelve-month revenue and $252 million net income, underscoring its established market position and ongoing research-led expansion.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop